AFQ065

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Smoking Abstinence

Conditions

Smoking Abstinence

Trial Timeline

Sep 1, 2006 → —

NCT ID

NCT00414752

About AFQ065

AFQ065 is a phase 1 stage product being developed by Novartis for Smoking Abstinence. The current trial status is completed. This product is registered under clinical trial identifier NCT00414752. Target conditions include Smoking Abstinence.

What happened to similar drugs?

17 of 20 similar drugs in Smoking Abstinence were approved

Approved (17) Terminated (0) Active (3)

✅Nicotine patch, nicotine inhaler, bupropion + Nicotine patchJohnson & JohnsonApproved

✅varenicline + placeboPfizerApproved

✅placebo + vareniclinePfizerApproved

✅Varenicline + PlaceboPfizerApproved

✅varenicline + vareniclinePfizerApproved

✅Varenicline Tartrate + PlaceboPfizerApproved

✅placebo + varenicline tartrate + bupropion hydrochloride + Nicotine Replacement Therapy PatchPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00414752	Phase 1	Completed	Sep 1, 2006	—	Smoking Abstinence

Competing Products

20 competing products in Smoking Abstinence

See all competitors

Product	Company	Stage	Hype Score
Brenipatide + Placebo	Eli Lilly	Phase 2	42
Nicotine + Nicotine + Nicotine	Johnson & Johnson	Phase 2	35
Nicotine replacement therapy + Nicotine replacement therapy	Johnson & Johnson	Phase 2	35
Nicotine Patch + Placebo Patch	Johnson & Johnson	Phase 1	29
Nicotine Patch + Placebo Patch + SLS Comparator Patch	Johnson & Johnson	Phase 1	29
Nicotine + Placebo	Johnson & Johnson	Pre-clinical	26
Nicotine Patch + Nicotine Patch Comparator + Placebo Patch	Johnson & Johnson	Phase 1	29
Nicotine Patch + Placebo Patch + No Patch Control	Johnson & Johnson	Phase 1	29
Nicotine gum + Placebo gum + Nicotine inhaler + Placebo inhaler	Johnson & Johnson	Phase 3	40
Nicotine patch, nicotine inhaler, bupropion + Nicotine patch	Johnson & Johnson	Approved	43
AZD4041 + Placebo	AstraZeneca	Phase 1	29
taranabant	Merck	Phase 2	35
Nicotine replacement therapy	Novartis	Pre-clinical	22
Liraglutide + Placebo	Novo Nordisk	Phase 2	35
Varenicline	Pfizer	Phase 2	35
placebo + Varenicline Tartarate	Pfizer	Phase 3	40
varenicline + placebo	Pfizer	Approved	39
varenicline (CP-526,555)	Pfizer	Phase 3	40
placebo + varenicline	Pfizer	Approved	43
Varenicline + Bupropion	Pfizer	Phase 3	40